What is cefepime used for in the emergency department?

Cefepime Use in the Emergency Department

Cefepime is a fourth-generation cephalosporin used in the ED primarily for empiric treatment of serious gram-negative infections requiring anti-pseudomonal coverage, including hospital-acquired pneumonia, febrile neutropenia, complicated intra-abdominal infections (with metronidazole), complicated urinary tract infections, and severe community-acquired pneumonia when resistant organisms are suspected. 1

Primary ED Indications

1. Hospital-Acquired/Ventilator-Associated Pneumonia

• Use cefepime 2 g IV every 8-12 hours for patients at high risk for multidrug-resistant (MDR) pathogens 2
• Indicated when local antibiograms show >90% susceptibility of gram-negative organisms to a single agent
• For patients in septic shock, combine with a second anti-pseudomonal agent (aminoglycoside or fluoroquinolone) plus MRSA coverage if >25% of S. aureus isolates are methicillin-resistant 2
• Provides coverage against Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, and ESBL-producing organisms 1

2. Febrile Neutropenia

• Cefepime monotherapy (2 g IV every 8 hours) is first-line for high-risk febrile neutropenic patients 3
• Covers P. aeruginosa and other serious gram-negative pathogens—the primary drivers of mortality in this population (18% mortality for gram-negatives vs 5% for gram-positives) 3
• FDA meta-analysis confirmed no statistically significant increase in mortality (RR 1.20,95% CI 0.82-1.76), resolving earlier safety concerns 3
• Do NOT add vancomycin routinely—reserve for specific indications (catheter-related infection, hemodynamic instability, suspected MRSA) 3

3. Complicated Intra-Abdominal Infections

• Always combine cefepime 2 g IV every 8-12 hours with metronidazole 500 mg IV every 8-12 hours 4, 1
• Cefepime lacks anaerobic coverage; metronidazole is mandatory 4, 5
• Appropriate for health care-associated infections or when ESBL-producing Enterobacteriaceae are suspected 4
• Alternative to carbapenems for carbapenem-sparing strategies 5

4. Complicated Urinary Tract Infections/Pyelonephritis

• Use when infection is severe or caused by resistant organisms 1
• Dose: 2 g IV every 12 hours for moderate infections; every 8 hours for severe infections 4

5. Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)

• Cefepime 2 g IV every 8-12 hours is acceptable when susceptibility testing confirms susceptibility 6
• For difficult-to-treat P. aeruginosa, consider newer agents (ceftolozane-tazobactam, ceftazidime-avibactam) if available 6

Dosing Considerations in the ED

Standard Dosing

• Pneumonia/Febrile Neutropenia: 2 g IV every 8 hours 4, 1
• Complicated UTI (moderate): 2 g IV every 12 hours 4
• Complicated intra-abdominal infections: 2 g IV every 8-12 hours 4

Renal Adjustment Critical

• Cefepime accumulates in renal impairment and causes neurotoxicity 7, 8
• For CrCl 30-60 mL/min: reduce to 1-2 g every 12-24 hours
• For CrCl <30 mL/min: reduce to 1 g every 24 hours or less
• Failure to adjust for renal function is the primary cause of cefepime-induced neurotoxicity (encephalopathy, seizures, myoclonus) 7, 8

Critical Safety Considerations

Neurotoxicity Risk

• Occurs in 6-15% of patients, especially with:
  • Renal impairment without dose adjustment
  • Pre-existing neurological conditions
  • Elderly patients
  • High doses (>6 g/day) 7, 9
• Monitor for confusion, myoclonus, seizures, especially if renal function deteriorates during therapy

Mortality Concerns

• Recent 2026 Bayesian meta-analysis showed 94.4% posterior probability of increased mortality vs other β-lactams (OR 1.10) 10
• However, this conflicts with FDA analysis and multiple guidelines that continue to recommend cefepime 3
• In practice: Use cefepime when anti-pseudomonal coverage is needed, but consider alternatives (piperacillin-tazobactam, carbapenems) for non-pseudomonal infections

When NOT to Use Cefepime

• Community-acquired pneumonia without risk factors for resistant organisms: Use ceftriaxone instead 2
• Mild-to-moderate community-acquired intra-abdominal infections: Use ertapenem, ceftriaxone, or fluoroquinolone + metronidazole 4
• Anaerobic infections alone: No anaerobic activity 4, 5
• MRSA coverage needed: Add vancomycin or linezolid 2
• Carbapenem-resistant Enterobacteriaceae: Cefepime is ineffective 6

ED-Specific Pitfalls

1. Forgetting metronidazole for intra-abdominal infections—cefepime has zero anaerobic coverage
2. Not adjusting for renal function—leads to neurotoxicity within 48-72 hours
3. Using for simple community-acquired infections—promotes resistance and increases costs unnecessarily 11
4. Assuming MRSA coverage—it doesn't cover MRSA; add vancomycin if needed
5. Monotherapy in septic shock with suspected MDR organisms—requires dual gram-negative coverage 2

Practical ED Algorithm

Step 1: Identify infection type and severity

• Severe HAP/VAP, febrile neutropenia, complicated IAI, or suspected MDR gram-negatives → Consider cefepime

Step 2: Check renal function immediately

• Adjust dose based on CrCl before second dose

Step 3: Add appropriate coverage

• Intra-abdominal: Add metronidazole (mandatory)
• Septic shock: Add second anti-pseudomonal agent
• MRSA risk: Add vancomycin or linezolid

Step 4: Obtain cultures before first dose

• Blood cultures, respiratory cultures, urine cultures as indicated 11

Step 5: Reassess at 48-72 hours

• De-escalate based on culture results and clinical response
• Monitor for neurotoxicity signs